Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-07

ACADIA PHARMACEUTICALS INC (ACAD)

CEO Catherine Owen Adams was paid $8,256,518 in fiscal year 2025, ↑ up 8.7% from fiscal year 2024, the 28th percentile of its disclosed peer group (SEC filing 0001193125-26-174163 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$8,256,518 ↑
Catherine Owen Adams total, FY2025
28th
CEO pay percentile vs peers
28.9:1
CEO-to-median pay ratio
98.73%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Catherine Owen Adams (Chief Executive Officer), FY2025 total compensation $8,256,518 (base salary $930,000) [exec_comp, SEC accession 0001193125-26-174163, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

ACAD's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗

Page 2 of 36 of the ACADIA PHARMACEUTICALS INC Executive Compensation Report, as it is delivered: Executive Summary.

That is page 2 of 36 of the full Executive Compensation Report, shown as it is delivered. The rest:

  1. Summary Compensation Table
  2. Equity transactions since the proxy statement
  3. Grants of plan-based awards
  4. Outstanding equity awards at fiscal year-end
  5. Incentive-plan design (CD&A)
  6. Say-on-pay
  7. CEO pay ratio
  8. Director compensation
  9. Board fee structure and ownership guideline
  10. Disclosed peer group
  11. Source register

Every figure above cites the filing it came from (accession 0001193125-26-174163, filed 2026-08-07) — see the source register, §11.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Catherine Owen Adams$930,000$0$3,240,558$3,234,797$818,559$0$32,604$8,256,518
Chief Executive Officer
Mark Schneyer546,42801,121,7271,119,738303,341028,1743,119,408
Executive Vice President, Chief Financial Officer
Jennifer Rhodes538,78301,035,9291,034,091299,104019,9902,927,897
Executive Vice President, Chief Legal Officer and Secretary
Elizabeth Thompson647,3250925,611923,958372,272019,2172,888,383
Executive Vice President, Head of Research and Development
Thomas Garner525,000000299,250032,773857,023
Executive Vice President, Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Catherine Owen Adams$8,256,518$7,594,107—↑ +662,411
Mark Schneyer3,119,4082,517,5132,591,204↑ +601,895
Jennifer Rhodes2,927,8973,267,348—↓ −339,451
Elizabeth Thompson2,888,3834,261,944—↓ −1,373,561
Thomas Garner857,0233,670,951—↓ −2,813,928

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read ACADIA PHARMACEUTICALS INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ACAD reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the ACADIA PHARMACEUTICALS INC Peer Teardown Report

$8,256,518 Catherine Owen Adams total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of August 7, 2026 · Source: 0001193125-26-174163 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for ACAD

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
ACADon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order ACAD

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against ACAD
40 companies name ACAD as a compensation peer

Each company listed discloses ACAD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ACAD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the ACADIA PHARMACEUTICALS INC Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Catherine Owen AdamsCEO$8,256,518
Elizabeth ThompsonEVP$2,888,383
Jennifer RhodesGeneral Counsel$2,927,897
Mark SchneyerCFO$3,119,408
Thomas GarnerCCO$857,023
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Adora NduIndependent Director$400,294
Daniel SolandFormer director (through FY2025)$387,589
Edmund P. HarriganIndependent Director$399,024
Elizabeth A. GarofaloIndependent Director$392,671
James M. DalyIndependent Director$393,942
Jonathan PooleIndependent Director—
Julian C. BakerDirector$385,049
Laura A. BregeIndependent Director$395,212
Stephen R. BiggarChair of the Board$415,542
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
James KiharaPRINCIPAL ACCOUNTING OFFICER2026-05-01A2,596——CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-05-01D6,81500Derivative, Class A CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-05-01A6,815——CommonForm 4 ↗
James KiharaPRINCIPAL ACCOUNTING OFFICER2026-05-01D2,59600Derivative, Class A CommonForm 4 ↗
James KiharaPRINCIPAL ACCOUNTING OFFICER2026-05-04D1,3322229,024CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-05-04D3,5062276,396CommonForm 4 ↗
James KiharaPRINCIPAL ACCOUNTING OFFICER2026-05-26D5,40121114,393CommonForm 4 ↗
James M. DalyDirector2026-05-29A9,31100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-29A18,62200CommonForm 4 ↗
Jonathan PooleDirector2026-05-29D2,01000Derivative, Class A CommonForm 4 ↗
Jonathan PooleDirector2026-05-29A2,010——CommonForm 4 ↗
Laura A. BregeDirector2026-05-29A9,31100Derivative, Class A CommonForm 4 ↗
Laura A. BregeDirector2026-05-29A16,00400Derivative, Class A CommonForm 4 ↗
Laura A. BregeDirector2026-05-29A8,107——CommonForm 4 ↗
Edmund P. HarriganDirector2026-05-29A16,00400Derivative, Class A CommonForm 4 ↗
James M. DalyDirector2026-05-29A16,00400Derivative, Class A CommonForm 4 ↗
James M. DalyDirector2026-05-29D8,10700Derivative, Class A CommonForm 4 ↗
James M. DalyDirector2026-05-29A8,107——CommonForm 4 ↗
Elizabeth A. GarofaloDirector2026-05-29A9,31100Derivative, Class A CommonForm 4 ↗
Elizabeth A. GarofaloDirector2026-05-29A16,00400Derivative, Class A CommonForm 4 ↗
Elizabeth A. GarofaloDirector2026-05-29D8,10700Derivative, Class A CommonForm 4 ↗
Elizabeth A. GarofaloDirector2026-05-29A8,107——CommonForm 4 ↗
Jonathan PooleDirector2026-05-29A9,31100Derivative, Class A CommonForm 4 ↗
Jonathan PooleDirector2026-05-29A16,00400Derivative, Class A CommonForm 4 ↗
Laura A. BregeDirector2026-05-29D8,10700Derivative, Class A CommonForm 4 ↗
Adora NduDirector2026-05-29A9,31100Derivative, Class A CommonForm 4 ↗
Adora NduDirector2026-05-29A16,00400Derivative, Class A CommonForm 4 ↗
Adora NduDirector2026-05-29D8,10700Derivative, Class A CommonForm 4 ↗
Adora NduDirector2026-05-29A8,107——CommonForm 4 ↗
Edmund P. HarriganDirector2026-05-29A9,31100Derivative, Class A CommonForm 4 ↗
Edmund P. HarriganDirector2026-05-29D8,10700Derivative, Class A CommonForm 4 ↗
Edmund P. HarriganDirector2026-05-29A8,107——CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-29A32,00800Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-29A32,00800Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-29A18,62200CommonForm 4 ↗
James KiharaPRINCIPAL ACCOUNTING OFFICER2026-06-26D11,42126297,912CommonForm 4 ↗
Elizabeth ThompsonEVP, Head of Research & Dev2026-07-29D32,27200Derivative, Class A CommonForm 4 ↗
Elizabeth ThompsonEVP, Head of Research & Dev2026-07-29A32,272——CommonForm 4 ↗
Elizabeth ThompsonEVP, Head of Research & Dev2026-07-30D50261,309CommonForm 4 ↗
Elizabeth ThompsonEVP, Head of Research & Dev2026-07-30D16,50826431,354CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-05A5,84918104,346CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-05D5,84900Derivative, Class A CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-05D5,84929169,638CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-06D14,29200Derivative, Class A CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-06D9,29229272,604CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-06D5,00029145,000CommonForm 4 ↗
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-06A14,29218254,969CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mark SchneyerOPTION2025-03-24——110,761—$1,119,738
Catherine Owen AdamsOPTION2025-03-24——319,976—3,234,797
Elizabeth ThompsonRSU2025-03-24—26,86126,861—462,815
Elizabeth ThompsonPSU2025-03-2410,60021,200—31,800462,796
Elizabeth H.Z.OPTION2025-03-24——91,395—923,958
Jennifer RhodesPSU2025-03-2411,86323,727—35,590517,960
Elizabeth ThompsonRSU2025-03-24—91,39591,395—923,958
Catherine Owen AdamsPSU2025-03-2437,11174,222—111,3331,620,266
Jennifer RhodesRSU2025-03-24——30,062—517,968
Jennifer RhodesOPTION2025-03-24——102,289—1,034,091
Catherine Owen AdamsRSU2025-03-24——94,039—1,620,292
Mark SchneyerRSU2025-03-24——32,552—560,871
Mark SchneyerPSU2025-03-2412,84625,692—38,538560,856
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mark Schneyer$560,871$560,856$1,119,73825.0%
Catherine Owen Adams1,620,2921,620,2663,234,79725.0%
Elizabeth Thompson1,386,773462,796025.0%
Elizabeth H.Z.00923,9580.0%
Jennifer Rhodes517,968517,9601,034,09125.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Catherine Owen AdamsPSU94,039—$2,511,782
Catherine Owen AdamsRSU94,039—2,511,782
Catherine Owen AdamsRSU110,393—2,948,597
Elizabeth ThompsonRSU21,200—566,252
Mark SchneyerRSU5,276—140,922
Elizabeth ThompsonRSU114,955—3,070,448
Mark SchneyerPSU19,544—522,020
Thomas GarnerRSU58,962—1,574,875
Catherine Owen AdamsRSU234,985—6,276,449
Elizabeth ThompsonPSU91,405—2,441,428
Mark SchneyerPSU69,994—1,869,540
Mark SchneyerPSU5,276—140,922
Jennifer RhodesOption68,57025.74—
Catherine Owen AdamsPSU160,763—4,293,980
Elizabeth ThompsonOption209,62715.29—
Catherine Owen AdamsPSU74,222—1,982,470
Mark SchneyerOption31,85321.75—
Elizabeth ThompsonOption91,39517.23—
Elizabeth ThompsonRSU64,544—1,723,970
Mark SchneyerRSU62,738—1,675,732
Jennifer RhodesRSU30,062—802,956
Jennifer RhodesRSU58,019—1,549,687
Jennifer RhodesRSU23,727—633,748
Jennifer RhodesPSU55,951—1,494,451
Thomas GarnerRSU45,372—1,211,886
Thomas GarnerPSU45,372—1,211,886
Mark SchneyerRSU32,552—869,464
Elizabeth ThompsonRSU26,861—717,457
Mark SchneyerPSU25,692—686,233
Jennifer RhodesRSU25,889—691,495
Mark SchneyerOption6,03525.75—
Jennifer RhodesPSU23,727—633,748
Elizabeth ThompsonPSU21,200—566,252
Mark SchneyerRSU18,536—495,097
Mark SchneyerRSU13,630—364,057
Mark SchneyerPSU6,815—182,029
Mark SchneyerPSU5,411—144,528
Catherine Owen AdamsOption242,86816.29—
Catherine Owen AdamsOption319,97617.23—
Mark SchneyerOption45,31817.84—
Mark SchneyerOption110,76117.23—
Jennifer RhodesOption102,28917.23—
Thomas GarnerOption176,88718.76—
05

Incentive-plan design — the Compensation Discussion & Analysis

CEO STI target (% of salary)80%
CEO LTI target (% of salary)—
Independent consultantFrederic W. Cook & Co., Inc. (FW Cook)
Clawback policytrue
Anti-hedging—
Anti-pledging—
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-29148,265,1731,911,358272,21698.73%Passed
20252025-05-29142,156,7542,807,251108,81498.06%Passed
20242024-05-29132,994,0187,639,777149,71894.57%Passed
20232023-06-0187,274,91748,257,939119,07164.34%Passed
20222022-06-07127,204,0123,387,622134,63297.31%Passed
20212021-06-22125,418,5102,400,666355,08697.85%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2998.73%a
20252025-05-2998.06%b
20242024-05-2994.57%c

a. Approved under the standard stated in the filing — “withheld votes will have no effect For or Withhold Not applicable No effect FOR all Board nominees 2 Advisory approval of the compensation of our named executive officers "For" votes from a majority of the votes cast on the matter (excluding abstentions and broker non-votes) For, Against or Abstain No effect No effect FOR 3 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 "For" votes from a majority of the votes cast on the matter ( er NYSE rules, meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions.”.

b. Approved under the standard stated in the filing — “withheld votes will have no effect For or Withhold Not applicable No effect FOR all Board nominees 2 Advisory approval of the compensation of our named executive officers "For" votes from a majority of the votes cast on the matter (excluding abstentions and broker non-votes) For, Against or Abstain No effect No effect FOR 3 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 "For" votes from a majority of the votes cast on the matter ( er NYSE rules, meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions.”.

c. Approved under the standard stated in the filing — “withheld votes will have no effect For or Withhold Not applicable No effect FOR all Board nominees 2 Advisory approval of the compensation of our named executive officers "For" votes from the holders of a majority of shares present at the meeting or represented by proxy and entitled to vote on the matter For, Against or Abstain Against No effect FOR 3 Approval of the Company's 2024 Equity Incentive Plan "For" votes from a majority of votes cast on this proposal For, Against or Abstain No effect (1) No effect FOR 4 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 "For" votes from the holders of a majority of shares present at the meeting or represented by proxy and entitled to vote on the matter For, Against or Abstain Against Not applicable (2) FOR (1) If you abstain from voting on a matter requiring a majority of the votes cast, your abstention will not affect the outcome of such vote because abstentions are not considered to be votes cast.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)28.9 : 1
CEO total compensation$8,256,518
Median employee compensation$286,045
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Stephen R. BiggarIndependent · Board Chair · Compensation (Chair) · Scientific Committee$58,445$180,705$176,392$0$0$415,542
Adora NduIndependent · Nominating and Corporate Governance · Scientific Committee43,199180,705176,39200400,294
Edmund P. HarriganIndependent · Audit · Compensation · Scientific Committee (Chair)41,928180,705176,39200399,024
Laura A. BregeIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance (Chair)38,116180,705176,39200395,212
James M. DalyIndependent · Audit · Compensation36,846180,705176,39200393,942
Elizabeth A. GarofaloIndependent · Compensation · Scientific Committee35,575180,705176,39200392,671
Daniel SolandIndependent · Audit (Chair) · Departed during FY30,493180,705176,39200387,589
Julian C. BakerNot independent · Nominating and Corporate Governance27,952180,705176,39200385,049
Catherine Owen AdamsEmployee director000000
Jonathan PooleIndependent · Audit000000
09

Board fee structure and ownership guideline

Annual cash retainer$150,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline✓ Have rigorous stock ownership guidelines
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$312,554
Equity awards (grant-date value)$1,445,640
All other compensation$0
Total cost of the board$1,758,194

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies ACADIA PHARMACEUTICALS INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including ACADIA PHARMACEUTICALS INC.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1PTC Therapeutics2025Matthew Klein$958,500$16,593,800$4,399,760$1,294,000$23,266,326
2Jazz Pharmaceuticals2025Renee Gala1,003,26916,138,43301,980,00019,151,558
3Rhythm Pharmaceuticals2025David Meeker807,6928,274,7857,688,560759,48817,544,525
4Supernus Pharmaceuticals2025Jack Khattar1,036,0006,535,0297,031,545846,93015,501,557
5Corcept Therapeutics2025Joseph Belanoff1,182,333012,907,718015,303,551
6Neurocrine Biosciences2025Kyle Gano920,0005,750,0235,750,006013,448,935
7Ionis Pharmaceuticals2025Brett Monia1,051,7768,444,8381,438,105013,350,777
8Biocryst Pharmaceuticals2025Jon Stonehouse728,466011,132,4581,052,63312,951,082
9Pacira BioSciences2025Frank Lee935,3089,215,5000738,81011,636,917
10Apellis Pharmaceuticals2024Cedric Francois793,1934,779,8324,787,768010,957,451
11Axsome Therapeutics2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
12Intra-Cellular Therapies2023Sharon Mates891,6537,749,9840010,086,413
13Amicus Therapeutics2024Bradley Campbell767,3084,990,3652,105,62708,526,943
14ACADIA PHARMACEUTICALS INC2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
15Dynavax Technologies2024Ryan Spencer835,0014,902,1501,824,299641,9078,210,775
16Harmony Biosciences2025Jeffrey Dayno743,6001,976,5204,599,000558,0007,899,535
17Catalyst Pharmaceuticals2024Richard Daly750,0001,267,6015,070,83007,774,160
18Sage Therapeutics2024Barry Greene830,7123,164,3642,669,263431,9707,112,589
19Ironwood Pharmaceuticals2025Thomas McCourt867,568411,6960650,6761,948,390

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
ACADIA PHARMACEUTICALS INC110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Amicus Therapeuticsnot disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Apellis Pharmaceuticals90.74%RSU 50 · PSU 50not disclosedPay Governance
Axsome Therapeutics150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Biocryst Pharmaceuticalsnot disclosednot disclosednot disclosedAon
Catalyst Pharmaceuticalsnot disclosednot disclosednot disclosedMercer LLC
Corcept TherapeuticsDr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%Stock Options 100not disclosednot disclosed
Dynavax Technologies102.5%Options 34 · RSU 33 · PSU 33Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology IndexAlpine
Harmony Biosciences100%not disclosednot disclosedPay Governance
Intra-Cellular Therapiesnot disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticalsnot disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Ironwood Pharmaceuticals100%RSU 50 · PSU 50not disclosedAlpine Rewards LLC
Jazz Pharmaceuticals150%PSU 50 · RSU 50Yes — Relative TSRAon
Neurocrine Biosciences105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Pacira BioSciences90%RSU 80 · PSU 20NoAon
PTC Therapeuticsnot disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Rhythm Pharmaceuticals120%Options 50 · RSU 50NoPay Governance
Sage Therapeutics80%not disclosedYes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology IndexAlpine Rewards
Supernus Pharmaceuticalsnot disclosednot disclosedNoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at ACADIA PHARMACEUTICALS INC in fiscal 2025?
As disclosed, Catherine Owen Adams (Chief Executive Officer) was the highest-paid executive at ACADIA PHARMACEUTICALS INC in fiscal 2025, with total compensation of $8,256,518.
How does ACADIA PHARMACEUTICALS INC's chief executive pay compare to its disclosed peer group?
As disclosed, Catherine Owen Adams's total compensation ranked at the 28th percentile of ACADIA PHARMACEUTICALS INC's disclosed peer group.
What is ACADIA PHARMACEUTICALS INC's CEO-to-median employee pay ratio?
As disclosed, ACADIA PHARMACEUTICALS INC's CEO-to-median employee pay ratio was 28.9:1.
How did shareholders vote on ACADIA PHARMACEUTICALS INC's executive compensation?
As disclosed, 98.73% of shareholders supported ACADIA PHARMACEUTICALS INC's executive compensation in the latest say-on-pay vote.
How much does ACADIA PHARMACEUTICALS INC spend in total on board compensation for fiscal 2025?
As disclosed, ACADIA PHARMACEUTICALS INC reported total board compensation of $1,758,194 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Catherine Owen AdamsDEF 14A2026-04-240001193125-26-174163Section “Executive Compensation”. As printed: 8,256,518. Filing ↗
2Section 01, Mark SchneyerDEF 14A2026-04-240001193125-26-174163Section “Executive Compensation”. As printed: 3,119,408. Filing ↗
3Section 01, Jennifer RhodesDEF 14A2026-04-240001193125-26-174163Section “Executive Compensation”. As printed: 2,927,897. Filing ↗
4Section 01, Elizabeth ThompsonDEF 14A2026-04-240001193125-26-174163Section “Executive Compensation”. As printed: 2,888,383. Filing ↗
5Section 01, Thomas GarnerDEF 14A2026-04-240001193125-26-174163Section “Executive Compensation”. As printed: 857,023. Filing ↗
6Section 03, Mark Schneyer OPTIONDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: t34 · r8 · c40 · span 1463841–1463850
7Section 03, Catherine Owen Adams OPTIONDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r5 · c7 · span 1714202–1714209
8Section 03, Elizabeth Thompson RSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: t34 · r17 · c40 · span 1602293–1602300
9Section 03, Elizabeth Thompson PSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r18 · c37 · span 1616846–1616853
10Section 03, Elizabeth H.Z. OPTIONDEF 14A2026-04-240001193125-26-174163Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1586753–1586760
11Section 03, Jennifer Rhodes PSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r14 · c37 · span 1555863–1555870
12Section 03, Elizabeth Thompson RSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r33 · c7 · span 2052879–2052885
13Section 03, Catherine Owen Adams PSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r6 · c40 · span 1432946–1432955
14Section 03, Jennifer Rhodes RSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r13 · c40 · span 1541310–1541317
15Section 03, Jennifer Rhodes OPTIONDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: t34 · r12 · c40 · span 1525784–1525793
16Section 03, Catherine Owen Adams RSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: t34 · r5 · c39 · span 1417421–1417430
17Section 03, Mark Schneyer RSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r9 · c40 · span 1479367–1479374
18Section 03, Mark Schneyer PSUDEF 14A2026-04-240001193125-26-174163Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r10 · c40 · span 1494889–1494896
19Section 07, pay ratioDEF 14A2026-04-240001193125-26-174163Section “CEO Pay Ratio”. As printed: 28.9 : 1. Filing ↗
20Section 08, Stephen R. BiggarDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 415,542. Filing ↗
21Section 08, Adora NduDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 400,294. Filing ↗
22Section 08, Edmund P. HarriganDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 399,024. Filing ↗
23Section 08, Laura A. BregeDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 395,212. Filing ↗
24Section 08, James M. DalyDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 393,942. Filing ↗
25Section 08, Elizabeth A. GarofaloDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 392,671. Filing ↗
26Section 08, Daniel SolandDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 387,589. Filing ↗machine: t48 · r9 · c19 · span 2594956–2594963
27Section 08, Julian C. BakerDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 385,049. Filing ↗
28Section 08, Catherine Owen AdamsDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 0. Filing ↗
29Section 08, Jonathan PooleDEF 14A2026-04-240001193125-26-174163Section “Director Compensation”. As printed: 0. Filing ↗
30Section 02, James Kihara 2026-05-01Form 42026-05-050001816160-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Mark Schneyer 2026-05-01Form 42026-05-050001899977-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Mark Schneyer 2026-05-01Form 42026-05-050001899977-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, James Kihara 2026-05-01Form 42026-05-050001816160-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, James Kihara 2026-05-04Form 42026-05-050001816160-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Mark Schneyer 2026-05-04Form 42026-05-050001899977-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, James Kihara 2026-05-26Form 42026-05-270001816160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, James M. Daly 2026-05-29Form 42026-06-010001560782-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, BAKER BROS. ADVISORS LP 2026-05-29Form 42026-06-020001193125-26-253632Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Jonathan Poole 2026-05-29Form 42026-06-010001604689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Jonathan Poole 2026-05-29Form 42026-06-010001604689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Laura A. Brege 2026-05-29Form 42026-06-010001365619-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Laura A. Brege 2026-05-29Form 42026-06-010001365619-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Laura A. Brege 2026-05-29Form 42026-06-010001365619-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Edmund P. Harrigan 2026-05-29Form 42026-06-010001177917-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, James M. Daly 2026-05-29Form 42026-06-010001560782-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, James M. Daly 2026-05-29Form 42026-06-010001560782-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, James M. Daly 2026-05-29Form 42026-06-010001560782-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Elizabeth A. Garofalo 2026-05-29Form 42026-06-010001826361-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Elizabeth A. Garofalo 2026-05-29Form 42026-06-010001826361-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Elizabeth A. Garofalo 2026-05-29Form 42026-06-010001826361-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Elizabeth A. Garofalo 2026-05-29Form 42026-06-010001826361-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Jonathan Poole 2026-05-29Form 42026-06-010001604689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Jonathan Poole 2026-05-29Form 42026-06-010001604689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Laura A. Brege 2026-05-29Form 42026-06-010001365619-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Adora Ndu 2026-05-29Form 42026-06-010001865210-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Adora Ndu 2026-05-29Form 42026-06-010001865210-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Adora Ndu 2026-05-29Form 42026-06-010001865210-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Adora Ndu 2026-05-29Form 42026-06-010001865210-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Edmund P. Harrigan 2026-05-29Form 42026-06-010001177917-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Edmund P. Harrigan 2026-05-29Form 42026-06-010001177917-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Edmund P. Harrigan 2026-05-29Form 42026-06-010001177917-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, BAKER BROS. ADVISORS LP 2026-05-29Form 42026-06-020001193125-26-253632Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, BAKER BROS. ADVISORS LP 2026-05-29Form 42026-06-020001193125-26-253632Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, BAKER BROS. ADVISORS LP 2026-05-29Form 42026-06-020001193125-26-253632Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, James Kihara 2026-06-26Form 42026-06-290001816160-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Elizabeth Thompson 2026-07-29Form 42026-07-310001861477-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Elizabeth Thompson 2026-07-29Form 42026-07-310001861477-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Elizabeth Thompson 2026-07-30Form 42026-07-310001861477-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Elizabeth Thompson 2026-07-30Form 42026-07-310001861477-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Mark Schneyer 2026-08-05Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Mark Schneyer 2026-08-05Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Mark Schneyer 2026-08-05Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Mark Schneyer 2026-08-06Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Mark Schneyer 2026-08-06Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Mark Schneyer 2026-08-06Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Mark Schneyer 2026-08-06Form 42026-08-070001899977-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
77Section 06, 2026 voteForm 8-K2026-05-290001193125-26-248242Item 5.07 · say-on-pay result. As reported: 98.73% (votes for as printed: 148,265,173). Filing ↗
78Section 06, 2025 voteForm 8-K2025-05-290001193125-25-130620Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 142,156,754). Filing ↗
79Section 06, 2024 voteForm 8-K2024-05-290001193125-24-149336Item 5.07 · say-on-pay result. As reported: 94.57% (votes for as printed: 132,994,018). Filing ↗
80Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
81Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
82Section 09b board cost (computed)Computed——Cash 312,554 + equity 1,445,640 + all other 0 = 1,758,194, summed across the director compensation table rows.machine: formula: Σ = 1,758,194
83PTC Therapeutics, Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗
84Jazz Pharmaceuticals, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
85Rhythm Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-290001628280-26-028375CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074
86Supernus Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-300001104659-26-053111CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604
87Corcept Therapeutics, Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514
88Neurocrine Biosciences, Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
89Ionis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗
90Biocryst Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in Biocryst Pharmaceuticals's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
91Pacira BioSciences, Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
92Apellis Pharmaceuticals, Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
93Axsome Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
94Intra-Cellular Therapies, Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
95Amicus Therapeutics, Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
96ACADIA PHARMACEUTICALS INC (subject), Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA PHARMACEUTICALS INC's own proxy. As printed: 8,256,518. Filing ↗
97Dynavax Technologies, Section 10b CEO totalDEF 14A2025-04-170000930413-25-001273CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗
98Harmony Biosciences, Section 10b CEO totalDEF 14A2026-04-030001104659-26-039449CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364
99Catalyst Pharmaceuticals, Section 10b CEO totalDEF 14A2025-04-110001193125-25-079097CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. Filing ↗
100Sage Therapeutics, Section 10b CEO totalDEF 14A2025-04-240000950170-25-058060CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793
101Ironwood Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191
102Section 10a, Apellis Pharmaceuticals reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
103Section 10a, Catalyst Pharmaceuticals reciprocityDEF 14A—0001193125-25-079097Catalyst Pharmaceuticals names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
104Section 10a, Dynavax Technologies reciprocityDEF 14A—0000930413-25-001273Dynavax Technologies names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
105Section 10a, Amicus Therapeutics reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
106Section 10a, Intra-Cellular Therapies reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
107Section 10a, Sage Therapeutics reciprocityDEF 14A—0000950170-25-058060Sage Therapeutics names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
108Section 10a, Ionis Pharmaceuticals reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
109Section 10a, Ironwood Pharmaceuticals reciprocityDEF 14A—0001104659-26-050325Ironwood Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include ACADIA PHARMACEUTICALS INC. Filing ↗
110Section 10a, Axsome Therapeutics reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics's most recent proxy was read; its disclosed peer group does not include ACADIA PHARMACEUTICALS INC. Filing ↗
111Section 10a, Jazz Pharmaceuticals reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include ACADIA PHARMACEUTICALS INC. Filing ↗
112Section 10a, Biocryst Pharmaceuticals reciprocityDEF 14A—0001628280-26-026822Biocryst Pharmaceuticals names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
113Section 10a, Neurocrine Biosciences reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
114Section 10a, Pacira BioSciences reciprocityDEF 14A—0001104659-26-050353Pacira BioSciences names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
115Section 10a, PTC Therapeutics reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
116Section 10a, Rhythm Pharmaceuticals reciprocityDEF 14A—0001628280-26-028375Rhythm Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include ACADIA PHARMACEUTICALS INC. Filing ↗
117Section 10a, Supernus Pharmaceuticals reciprocityDEF 14A—0001104659-26-053111Supernus Pharmaceuticals names ACADIA PHARMACEUTICALS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
118Section 10a, Harmony Biosciences reciprocityDEF 14A—0001104659-26-039449Harmony Biosciences's most recent proxy was read; its disclosed peer group does not include ACADIA PHARMACEUTICALS INC. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the ACADIA PHARMACEUTICALS INC Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
ACAD Peer Teardown Report